A blood test can find a cancer signal. Can the care system deliver the benefit?

The decision in front of the field

On September 23, 2026, an FDA advisory panel reviewed GRAIL's Galleri application. The proposed prescription test analyzes methylation patterns in cell-free DNA from blood to identify a cancer signal and predict its likely origin in adults 50 or older. The panel voted 10–0 on reasonable assurance of safety, 6–4 on effectiveness, and 7–2 with one abstention that benefits outweigh risks for the proposed population. These are advisory votes, not an FDA approval decision.

The important story for laboratories is larger than one product. A test can be analytically sophisticated, highly specific, and useful for some patients while the evidence for population-level benefit remains uncertain. My view is that leaders should evaluate the entire pathway from specimen collection to confirmed diagnosis, rather than treat a performance number as a purchasing decision.

What the performance numbers mean

In FDA's summary, the U.S. PATHFINDER 2 analysis reported 35.0% overall 12-month episode sensitivity and 99.85% specificity. The NHS-Galleri analysis reported 31.6% sensitivity and 99.74% specificity. Those estimates describe performance in the studied populations and time windows; they are not promises for every hospital, cancer type, or patient group.

Specificity near 99.8% is impressive, but a screening program tests many people without cancer. False positives still lead to calls, imaging, specialist visits, possible procedures, uncertainty, and cost. Sensitivity is equally important: a negative result cannot reassure someone that cancer is absent. FDA's own materials say routine, guideline-recommended screening should continue.

The overall average conceals major differences. FDA's NHS-Galleri summary estimated 13.6% sensitivity for stage I cancers and 60.0% for stage IV cancers among staged new cancers in that analysis. The panel questioned whether a broad 'early detection' claim was supported. A director should request results by cancer type and stage, confidence intervals, subgroup data, and the exact intended-use population before judging whether a headline figure is relevant locally.

Regulatory status is not a clinical outcome

CLIA certification governs the laboratory and the quality of testing it performs. FDA premarket review considers a device's proposed use, performance, and benefit-risk evidence. A CLIA-certified laboratory offering a test does not mean FDA has approved that test. An FDA advisory committee recommendation also does not itself grant approval.

The broader laboratory-developed-test policy remains important but should not be reduced to a slogan. The 2024 FDA LDT final rule was vacated by a court in March 2025; FDA reverted the regulation's text in September 2025. A laboratory assessing a particular product still needs to identify its actual regulatory status, the entity performing the assay, applicable CLIA obligations, any FDA decision, state rules, payer terms, and the responsibilities in its own service agreement.

Regulatory permission, reimbursement, and clinical utility answer separate questions. Permission establishes what can be offered under the applicable framework. Reimbursement determines who may pay under a specific policy. Clinical utility asks whether use changes care in a way that produces a meaningful net benefit for patients.

The outcomes question is still open

The randomized NHS-Galleri trial did not meet its prespecified primary endpoint of a statistically significant reduction in combined stage III and IV diagnoses among 12 selected cancer types over the study period. Investigators reported secondary and later-round signals that warrant continued study, but a favorable secondary finding does not erase a missed primary endpoint. The FDA panel also noted that long-term impact on patient outcomes has not been established.

Earlier detection is valuable when it leads to treatment that changes the course of disease. It can also generate lead-time bias, overdiagnosis, unnecessary workups, or false reassurance if a negative result displaces proven screening. The outcome measures I would ask for are fewer advanced cancers, cancer-specific mortality when available, treatment options gained, diagnostic burden, complications, and equitable follow-up across patient groups.

The panel saw the clearest potential in cancers without existing guideline-recommended screening. It emphasized that Galleri should not replace established breast, colorectal, cervical, or lung screening programs. That distinction should appear in ordering guidance, result language, and clinician education.

What a lab director and executive team should require

Before introducing a multicancer screening pathway, put a multidisciplinary review in writing. The laboratory should examine preanalytical controls, sample transport, test limitations, report design, and interface integrity. Oncology and primary care leaders should define the positive-result workup, referral capacity, and a closed-loop follow-up owner. Finance should model the full episode, including repeat testing, imaging, consultation, downstream procedures, and patient out-of-pocket exposure.

A small, controlled evaluation may be more defensible than an organization-wide launch while evidence and payer policy evolve. Set eligibility rules, a defined patient communication script, escalation responsibilities, audit fields, and stopping rules. Track whether patients still complete standard screening and whether every positive result reaches diagnostic resolution.

• Evidence: intended use, cancer- and stage-specific sensitivity, specificity, predictive values, confidence intervals, clinical outcomes, and limitations.
• Regulation: current FDA status, CLIA and state requirements, performing laboratory, labeling, and written responsibility for changes.
• Operations: sample stability, result routing, diagnostic referral capacity, closed-loop follow-up, and patient communication.
• Economics: test price, coverage and prior authorization, follow-up costs, staff time, and measures of real benefit rather than test volume alone.
• Equity: access to confirmatory care, subgroup evidence, language support, and financial barriers after a positive result.

AssayIQ's position

This technology deserves rigorous evaluation and continued research. It should neither be dismissed because a primary endpoint was missed nor promoted as a universal early-cancer answer because a panel voted favorably on benefit-risk. The right decision depends on the defined population, the evidence for the actual claim, and the organization's ability to deliver timely and affordable follow-up.

AssayIQ can help a laboratory or health system organize an independent evidence review, map the specimen-to-diagnosis workflow, compare current and proposed costs, draft decision criteria, and build a monitoring dashboard. The medical, regulatory, and adoption decisions remain with authorized clinical and organizational leadership.